Disease-Modifying Therapies in Multiple Sclerosis: A Focused Review of Rituximab.

Rituximab should be considered as both a first-line and second-line therapy option for most MS patients with active, non-progressive disease. However, as an off-label therapy for MS, regulatory approval remains a barrier for wider adoption in many countries.